• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种简单的肝细胞癌负担衡量指标可预测肝移植后肿瘤复发:复发性肝细胞癌-初始、最大、末次分类。

A Simple Measure of Hepatocellular Carcinoma Burden Predicts Tumor Recurrence After Liver Transplantation: The Recurrent Hepatocellular Carcinoma-Initial, Maximum, Last Classification.

机构信息

Center for Liver Investigation Fostering Discovery, University of Washington, Seattle, WA.

Division of Gastroenterology and Hepatology, University of Washington, Seattle, WA.

出版信息

Liver Transpl. 2019 Apr;25(4):559-570. doi: 10.1002/lt.25422.

DOI:10.1002/lt.25422
PMID:30706653
Abstract

Risk of recurrent hepatocellular carcinoma (rHCC) after liver transplantation (LT) depends on the pre-LT HCC burden, tumor behavior, and response to locoregional therapy (LRT). In December 2017, LT priority for HCC was expanded to select patients outside the Milan criteria who respond to LRT. Our aims were to develop a novel objective measure of pre-LT HCC burden (model of recurrent hepatocellular carcinoma-initial, maximum, last [RH-IML]), incorporating tumor behavior over time, and to apply RH-IML to model post-LT rHCC. Using United Network for Organ Sharing data from between 2002-2014 (development) and 2015-2017 (validation), we identified adult LT recipients with HCC and assessed pre-LT HCC tumor behavior and post-LT rHCC. For each patient, HCC burden was measured at 3 points on the waiting list: initial (I), maximum (M) total tumor diameter, and last (L) exception petition. HCC burden at these 3 points were classified as (A) <Milan, (B) Milan, (C) >Milan to University of California, San Francisco (UCSF), and (D) >UCSF, resulting in each patient having a 3-letter RH-IML designation. Of 16,558 recipients with HCC, 1233 (7%) had any post-LT rHCC. rHCC rates were highest in RH-IML group CCC (15%) and DDD (18%). When M and L tumor burdens did not exceed Milan (class B or A), rHCC was low (≤10%) as in AAA, ABA, ABB, BBA, BBB; rHCC was also low (≤10%) with successful downstaging when L was A (<Milan) and M tumor burden did not exceed I, as in BBA, CCA, and DDA. In conclusion, the RH-IML classification system is a simple summative measure of HCC burden that incorporates tumor behavior over time. RH-IML also estimates post-LT rHCC risk and is a useful tool for evaluating risk for rHCC post-LT.

摘要

移植后肝癌(rHCC)的复发风险取决于移植前 HCC 的负担、肿瘤行为和局部区域治疗(LRT)的反应。2017 年 12 月,将 HCC 的 LT 优先扩展到符合米兰标准但对 LRT 有反应的患者。我们的目的是开发一种新的移植前 HCC 负担的客观测量方法(复发性肝癌初始、最大、最后模型[RH-IML]),该方法将随时间推移的肿瘤行为纳入其中,并将 RH-IML 应用于模型后 LT rHCC。使用 2002-2014 年(开发)和 2015-2017 年(验证)期间的 United Network for Organ Sharing 数据,我们确定了患有 HCC 的成年 LT 受者,并评估了移植前 HCC 肿瘤行为和移植后 rHCC。对于每个患者,HCC 负担在等待名单上的 3 个点进行测量:初始(I)、最大(M)总肿瘤直径和最后(L)例外请求。将这 3 个点的 HCC 负担分类为(A)<Milan,(B)Milan,(C)>Milan 至加利福尼亚大学旧金山分校(UCSF)和(D)>UCSF,从而使每个患者具有 3 个字母的 RH-IML 标记。在 16558 名患有 HCC 的受者中,有 1233 名(7%)发生任何移植后 rHCC。RH-IML 组 CCC(15%)和 DDD(18%)的 rHCC 发生率最高。当 M 和 L 肿瘤负担不超过米兰(B 或 A 类)时,rHCC 发生率较低(≤10%),如 AAA、ABA、ABB、BBA、BBB;当 L 为 A(<Milan)且 M 肿瘤负担不超过 I 时,rHCC 也较低(≤10%),如 BBA、CCA 和 DDA。结论:RH-IML 分类系统是一种简单的 HCC 负担累积测量方法,它随时间推移纳入了肿瘤行为。RH-IML 还估计了移植后 rHCC 的风险,是评估移植后 rHCC 风险的有用工具。

相似文献

1
A Simple Measure of Hepatocellular Carcinoma Burden Predicts Tumor Recurrence After Liver Transplantation: The Recurrent Hepatocellular Carcinoma-Initial, Maximum, Last Classification.一种简单的肝细胞癌负担衡量指标可预测肝移植后肿瘤复发:复发性肝细胞癌-初始、最大、末次分类。
Liver Transpl. 2019 Apr;25(4):559-570. doi: 10.1002/lt.25422.
2
A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients.一种新型预后列线图可准确预测肝移植后肝细胞癌复发:对865例连续肝移植受者的分析
J Am Coll Surg. 2015 Apr;220(4):416-27. doi: 10.1016/j.jamcollsurg.2014.12.025. Epub 2014 Dec 27.
3
Rate of tumor growth predicts recurrence of hepatocellular carcinoma after liver transplantation in patients beyond Milan or UCSF criteria.肿瘤生长速率可预测超出米兰或加州大学旧金山分校标准的患者肝移植后肝细胞癌的复发情况。
Transplant Proc. 2011 Dec;43(10):3813-8. doi: 10.1016/j.transproceed.2011.09.043.
4
Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.同型半胱氨酸:甲胎蛋白阴性肝细胞癌肝移植的新型预后生物标志物。
Cancer Biomark. 2020;29(2):197-206. doi: 10.3233/CBM-201545.
5
National Experience on Down-Staging of Hepatocellular Carcinoma Before Liver Transplant: Influence of Tumor Burden, Alpha-Fetoprotein, and Wait Time.国家在肝移植前对肝细胞癌降期的经验:肿瘤负担、甲胎蛋白和等待时间的影响。
Hepatology. 2020 Mar;71(3):943-954. doi: 10.1002/hep.30879. Epub 2019 Oct 15.
6
Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.对超出米兰标准的肝细胞癌患者进行降期治疗:使用载药微球化疗栓塞的策略
J Vasc Interv Radiol. 2013 Nov;24(11):1613-22. doi: 10.1016/j.jvir.2013.07.024. Epub 2013 Sep 20.
7
Alpha-Fetoprotein Slope >7.5 ng/mL per Month Predicts Microvascular Invasion and Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma.甲胎蛋白斜率>7.5ng/ml/月预测肝癌肝移植后微血管侵犯和肿瘤复发。
Transplantation. 2018 May;102(5):816-822. doi: 10.1097/TP.0000000000002094.
8
Liver Transplantation Outcomes in a U.S. Multicenter Cohort of 789 Patients With Hepatocellular Carcinoma Presenting Beyond Milan Criteria.美国多中心队列 789 例米兰标准以外的肝细胞癌患者肝移植结局。
Hepatology. 2020 Dec;72(6):2014-2028. doi: 10.1002/hep.31210.
9
Outcomes of Liver Transplantation for Hepatocellular Carcinoma Beyond the University of California San Francisco Criteria: A Single-center Experience.加利福尼亚大学旧金山标准之外的肝癌肝移植治疗结果:单中心经验。
Transplantation. 2020 Jan;104(1):113-121. doi: 10.1097/TP.0000000000002835.
10
The mRECIST Classification Provides Insight into Tumor Biology for Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation.mRECIST 分类为等待肝移植的肝细胞癌患者提供了肿瘤生物学的深入了解。
Liver Transpl. 2019 Feb;25(2):228-241. doi: 10.1002/lt.25333.

引用本文的文献

1
Prognostic role of selection criteria for liver transplantation in patients with hepatocellular carcinoma: a network meta-analysis.肝癌患者肝移植选择标准的预后作用:网络荟萃分析。
BJS Open. 2022 Jan 6;6(1). doi: 10.1093/bjsopen/zrab130.
2
Liver Transplantation in Malignancies: A Comprehensive and Systematic Review on Oncological Outcome.恶性肿瘤中的肝移植:关于肿瘤学结局的全面系统综述
Visc Med. 2021 Aug;37(4):302-314. doi: 10.1159/000517328. Epub 2021 Jul 29.
3
Essential updates 2018/2019: Liver transplantation.2018/2019年重要更新:肝移植
Ann Gastroenterol Surg. 2020 Feb 25;4(3):195-207. doi: 10.1002/ags3.12321. eCollection 2020 May.